The Centres of Excellence for Commercialization and Research framework (CECR) enabled PC-TRiADD to build a solid foundation and gain momentum toward our objectives.  Since our inception in 2008, we have:

  • Attracted over $18 million in research contracts and $92.1 million in peer-reviewed funding, through the structuring of our core platforms to form an integrated contract research enterprise
  • Expanded High Quality Personnel and management to include an experienced executive team
  • Expanded our portfolio of IP protected targets and drug candidates that tackle treatment resistance that are translating into commercialization activities, with 277 patents filed/issued
  • Established 9 licensing agreements of IP with industry (8 drug, 1 biomarker)
  • Attracted increased global funding allowing us to initiate 125 new clinical trials, the majority of which are either peer reviewed, grant funded or are sponsored by pharmaceutical companies


Jul 26 2017

Dr. Zoubeidi awarded PCC-Movember Translation Acceleration Grant

July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.

Read more